XEROS TECHNOLOGY GROUP PLC

Share Issue/Capital Change • Jul 26, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8587G

Xeros Technology Group plc

26 July 2019

BLOCK LISTING SIX MONTHLY RETURN

The Company gives below the information required by Schedule 6 of the AIM Rules for Companies in connection with the Xeros Technology Group plc Enterprise Management Incentive Scheme and the Xeros Technology Group plc unapproved share option scheme.

Date: 26 July 2019

Name of applicant:		Xeros Technology Group Plc
Name of scheme:		Xeros Technology Group plc Enterprise Management Incentive Scheme ("EMI") & Xeros Technology Group plc unapproved share option scheme ("USOS")
Period of return:	From:	1 January 2019	To:	30 June 2019
Balance of unallotted securities under scheme(s) from previous return:		EMI: 904,338 ordinary shares of 0.15p each USOS: 1,986,562 ordinary shares of 0.15p each
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		EMI: nil ordinary shares of 0.15p each USOS: nil ordinary shares of 0.15p each
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		EMI: nil ordinary shares of 0.15p each USOS: 17,094 ordinary shares of 0.15p each
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		EMI: 904,338 ordinary shares of 0.15p each USOS: 1,969,468 ordinary shares of 0.15p each
Number and class of securities originally admitted and the date of admission:		EMI: 1,750,000 ordinary shares of 0.15p each on 27 January 2015 USOS: 313,166 ordinary shares of 0.15p each on 27 January 2015

Name of contact:	Paul Denney, Company Secretary
Telephone number of contact:	0114 2699656

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BLRUNRWRKSABURR